<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890266</url>
  </required_header>
  <id_info>
    <org_study_id>CHAR1006</org_study_id>
    <secondary_id>08/H0721/15</secondary_id>
    <nct_id>NCT00890266</nct_id>
  </id_info>
  <brief_title>Corneal Collagen Cross-linking With Hypotonic Riboflavin in Corneas Thinner Than 400 Microns</brief_title>
  <acronym>HypotonicRibo</acronym>
  <official_title>Collagen Cross-linking With Riboflavin in a Hypotonic Solution, With UV Light, on Corneas Less Than 400 Microns Thick: an Exploratory Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peschke Meditrade, GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Moorfields Eye Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Corneal ectasia is a relative weakness in the structure of the cornea, which produces a
      progressive change in its shape which results in visual distortion. It is known that collagen
      cross-linking in the cornea occurs naturally with age, and in diabetes, both of which seem to
      prevent progressive ectasia. Corneal collagen cross-linking with riboflavin on corneas
      thicker than 400 microns has been shown to stabilize the cornea in keratoconus, and prevent
      progression of the disease.

      The purpose of this study is to determine whether corneal collagen cross-linking with
      riboflavin in a hypotonic solution, with UV light, on corneas less than 400 microns thick,
      leads to stabilisation of corneal ectasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When cross-linking corneas of &gt; 400 microns, riboflavin in a solution with high molecular
      weight dextran T500 is used to prevent corneal swelling during the administration of the
      drops and the UV treatment. However if riboflavin is applied to a cornea in a hypotonic
      solution (saline), then transient corneal oedema is created with thickening of the corneal
      stroma. In this way it is thought that the temporarily thickened cornea can be treated with
      UV whilst still providing a sufficient thickness to absorb the UV to an extent that
      endothelial cell damage is avoided.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">July 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in keratometry/corneal topography</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal endothelial cell count</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Keratoconus</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collagen cross-linking with hypotonic riboflavin</intervention_name>
    <description>Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).</description>
    <other_name>Medio-CrossÂ® hypotonic solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Keratoconus

          -  Corneas thinner than 400 microns, but thicker than 250 microns

        Exclusion Criteria:

          -  Evidence of other corneal disease in the eye to be treated (e.g., Herpes simplex
             keratitis)

          -  Women who are pregnant or nursing at the time of the initial treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad K Rostron, FRCOphth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moorfields Eye Department at St George's Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW17 0QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.chadrostron.co.uk/Assets/HypotonicRiboflavinCrossLinkingPatientInfoV1.2.pdf</url>
    <description>Patient information sheet.</description>
  </link>
  <link>
    <url>http://www.chadrostron.co.uk/Assets/HypotonicRiboflavinCrossLinkingProtocolV1.3.pdf</url>
    <description>Protocol</description>
  </link>
  <reference>
    <citation>Hafezi F, Mrochen M, Iseli HP, Seiler T. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin corneas. J Cataract Refract Surg. 2009 Apr;35(4):621-4. doi: 10.1016/j.jcrs.2008.10.060.</citation>
    <PMID>19304080</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 27, 2009</study_first_submitted>
  <study_first_submitted_qc>April 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2009</study_first_posted>
  <last_update_submitted>May 6, 2010</last_update_submitted>
  <last_update_submitted_qc>May 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mr Chad K Rostron</name_title>
    <organization>Moorfields Eye Department at St. George's Hospital.</organization>
  </responsible_party>
  <keyword>keratoconus</keyword>
  <keyword>collagen cross-linking</keyword>
  <keyword>riboflavin</keyword>
  <keyword>UV light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

